Listing by drug (A-Z)

Aceclofenac

Site-specificity, with state-dependency… the perfect anti-arthritic agent?

New teachings describe the “perfect anti-arthritic agent”; acceptance by KOLs offers unprecedented prospects.
Read the full report

Client:
UCB (under licence with Almirall Prodesfarma)
Category:
Musculoskeletal

Amitriptyline

Is refractory cough a neuropathy?

New teachings mean new IP and a new indication for fifty-year old tricyclic anti-depressant.
Read the full report

Client:
PPG
Category:
Respiratory

Azapropazone

Why is the elderly female at high risk for NSAID-induced gastric damage?

New teachings provide robust differentiation that rapidly translates into revenue in a very crowded NSAID market.
Read the full report

Client:
A H Robins; Wyeth
Category:
Musculoskeletal

Buprenorphine

A new landmark in the treatment of chronic pain

Previously-unknown relationship between ultra-low dose naloxone and buprenorphine fulfills void in pain management.
Read the full report

Client:
Reckitt & Colman
Category:
Pain

Buprenorphine

A cardioprotective analgesic for acute MI?

Historical data suggest previously-unknown cardioprotective effects of buprenorphine.
Read the full report

Client:
Reckitt & Colman
Category:
Pain

Captopril

Is a thirty-year old drug the new way in managing post MI?

CEME enables powerful differentiation of a thirty-year old drug as ACE inhibitor of choice in the post MI patient.
Read the full report

Client:
GSK (under licence with BMS for Capoten brand)
Category:
Cardiovascular

Captopril

A new era in surgery… scar-free wound healing

McCormack’s methods identify new hope for attaining scar-free wound healing.
Read the full report

Client:
PPG
Category:
Wound Healing

Clopidogrel

Has CEME solved the problem of variability in response to clopidogrel?

CEME identifies previously-unknown relationships that provide a new explanation for variability in response to top anti-platelet drug, and new teachings mean new opportunities in emerging markets.
Read the full report

Client:
GSK (under licence with BMS for Plavix brand)
Category:
Cardiovascular

Diclofenac (Intravenous)

Reformulated diclofenac has the potential to target neuropathic pain

New targets for reformulated diclofenac mean that an established drug offers hope to millions of patients with chronic pain.
Read the full report

Client:
Javelin
Category:
Pain

Divalproex

Using chaos theory to explain how divalproex treats bipolar disorder

CEME identifies chaos theory as a basis for the efficacy of divalproex, and space-filling models confirm that uniquely, divalproex self-assembles.
Read the full report

Client:
Sanofi-Synthelabo
Category:
Central nervous system

Donepezil

Using donepezil to diagnose Alzheimer’s disease?

New opportunities for leading Alzheimer drug.
Read the full report

Client:
Eisai/Pfizer
Category:
Central nervous system

Ketoprofen

Defining a new class of analgesic

CEME identifies novel mechanism of action that differentiates ketoprofen as analgesic of choice in peri-operative pain management. Orudis becomes positioned as blockbuster.
Read the full report

Client:
Rhone-Poulenc Rorer (RPR)
Category:
Pain

Potassium nitrate (Oral)

New teachings support the use of potassium in managing dentine sensitivity

New teachings mean market leadership through control of the dentine sensitivity market.
Read the full report

Client:
Colgate-Oral Pharmaceuticals
Category:
Oral

Zolpidem

New meta-analysis shows that zolpidem preserves sleep architecture

McCormack’s methods yield dramatic visualization of the novel effects of a leading hypnotic upon sleep architecture.
Read the full report

Client:
Sanofi
Category:
Central nervous system

Captopril

Is a thirty-year old drug the new way in managing post MI?

CEME enables powerful differentiation of a thirty-year old drug as ACE inhibitor of choice in the post MI patient.
Read the full report

Client:
GSK (under licence with BMS for Capoten brand)
Category:
Cardiovascular

Clopidogrel

Has CEME solved the problem of variability in response to clopidogrel?

CEME identifies previously-unknown relationships that provide a new explanation for variability in response to top anti-platelet drug, and new teachings mean new opportunities in emerging markets.
Read the full report

Client:
GSK (under licence with BMS for Plavix brand)
Category:
Cardiovascular

Divalproex

Using chaos theory to explain how divalproex treats bipolar disorder

CEME identifies chaos theory as a basis for the efficacy of divalproex, and space-filling models confirm that uniquely, divalproex self-assembles.
Read the full report

Client:
Sanofi-Synthelabo
Category:
Central nervous system

Donepezil

Using donepezil to diagnose Alzheimer’s disease?

New opportunities for leading Alzheimer drug.
Read the full report

Client:
Eisai/Pfizer
Category:
Central nervous system

Zolpidem

New meta-analysis shows that zolpidem preserves sleep architecture

McCormack’s methods yield dramatic visualization of the novel effects of a leading hypnotic upon sleep architecture.
Read the full report

Client:
Sanofi
Category:
Central nervous system

Aceclofenac

Site-specificity, with state-dependency… the perfect anti-arthritic agent?

New teachings describe the “perfect anti-arthritic agent”; acceptance by KOLs offers unprecedented prospects.
Read the full report

Client:
UCB (under licence with Almirall Prodesfarma)
Category:
Musculoskeletal

Azapropazone

Why is the elderly female at high risk for NSAID-induced gastric damage?

New teachings provide robust differentiation that rapidly translates into revenue in a very crowded NSAID market.
Read the full report

Client:
A H Robins; Wyeth
Category:
Musculoskeletal

Potassium nitrate (Oral)

New teachings support the use of potassium in managing dentine sensitivity

New teachings mean market leadership through control of the dentine sensitivity market.
Read the full report

Client:
Colgate-Oral Pharmaceuticals
Category:
Oral

Buprenorphine

A new landmark in the treatment of chronic pain

Previously-unknown relationship between ultra-low dose naloxone and buprenorphine fulfills void in pain management.
Read the full report

Client:
Reckitt & Colman
Category:
Pain

Buprenorphine

A cardioprotective analgesic for acute MI?

Historical data suggest previously-unknown cardioprotective effects of buprenorphine.
Read the full report

Client:
Reckitt & Colman
Category:
Pain

Diclofenac (Intravenous)

Reformulated diclofenac has the potential to target neuropathic pain

New targets for reformulated diclofenac mean that an established drug offers hope to millions of patients with chronic pain.
Read the full report

Client:
Javelin
Category:
Pain

Ketoprofen

Defining a new class of analgesic

CEME identifies novel mechanism of action that differentiates ketoprofen as analgesic of choice in peri-operative pain management. Orudis becomes positioned as blockbuster.
Read the full report

Client:
Rhone-Poulenc Rorer (RPR)
Category:
Pain

Amitriptyline

Is refractory cough a neuropathy?

New teachings mean new IP and a new indication for fifty-year old tricyclic anti-depressant.
Read the full report

Client:
PPG
Category:
Respiratory

Captopril

A new era in surgery… scar-free wound healing

McCormack’s methods identify new hope for attaining scar-free wound healing.
Read the full report

Client:
PPG
Category:
Wound Healing

Azapropazone

Why is the elderly female at high risk for NSAID-induced gastric damage?

New teachings provide robust differentiation that rapidly translates into revenue in a very crowded NSAID market.
Read the full report

Client:
A H Robins; Wyeth
Category:
Musculoskeletal

Potassium nitrate (Oral)

New teachings support the use of potassium in managing dentine sensitivity

New teachings mean market leadership through control of the dentine sensitivity market.
Read the full report

Client:
Colgate-Oral Pharmaceuticals
Category:
Oral

Donepezil

Using donepezil to diagnose Alzheimer’s disease?

New opportunities for leading Alzheimer drug.
Read the full report

Client:
Eisai/Pfizer
Category:
Central nervous system

Captopril

Is a thirty-year old drug the new way in managing post MI?

CEME enables powerful differentiation of a thirty-year old drug as ACE inhibitor of choice in the post MI patient.
Read the full report

Client:
GSK (under licence with BMS for Capoten brand)
Category:
Cardiovascular

Clopidogrel

Has CEME solved the problem of variability in response to clopidogrel?

CEME identifies previously-unknown relationships that provide a new explanation for variability in response to top anti-platelet drug, and new teachings mean new opportunities in emerging markets.
Read the full report

Client:
GSK (under licence with BMS for Plavix brand)
Category:
Cardiovascular

Diclofenac (Intravenous)

Reformulated diclofenac has the potential to target neuropathic pain

New targets for reformulated diclofenac mean that an established drug offers hope to millions of patients with chronic pain.
Read the full report

Client:
Javelin
Category:
Pain

Amitriptyline

Is refractory cough a neuropathy?

New teachings mean new IP and a new indication for fifty-year old tricyclic anti-depressant.
Read the full report

Client:
PPG
Category:
Respiratory

Captopril

A new era in surgery… scar-free wound healing

McCormack’s methods identify new hope for attaining scar-free wound healing.
Read the full report

Client:
PPG
Category:
Wound Healing

Buprenorphine

A new landmark in the treatment of chronic pain

Previously-unknown relationship between ultra-low dose naloxone and buprenorphine fulfills void in pain management.
Read the full report

Client:
Reckitt & Colman
Category:
Pain

Buprenorphine

A cardioprotective analgesic for acute MI?

Historical data suggest previously-unknown cardioprotective effects of buprenorphine.
Read the full report

Client:
Reckitt & Colman
Category:
Pain

Ketoprofen

Defining a new class of analgesic

CEME identifies novel mechanism of action that differentiates ketoprofen as analgesic of choice in peri-operative pain management. Orudis becomes positioned as blockbuster.
Read the full report

Client:
Rhone-Poulenc Rorer (RPR)
Category:
Pain

Zolpidem

New meta-analysis shows that zolpidem preserves sleep architecture

McCormack’s methods yield dramatic visualization of the novel effects of a leading hypnotic upon sleep architecture.
Read the full report

Client:
Sanofi
Category:
Central nervous system

Divalproex

Using chaos theory to explain how divalproex treats bipolar disorder

CEME identifies chaos theory as a basis for the efficacy of divalproex, and space-filling models confirm that uniquely, divalproex self-assembles.
Read the full report

Client:
Sanofi-Synthelabo
Category:
Central nervous system

Aceclofenac

Site-specificity, with state-dependency… the perfect anti-arthritic agent?

New teachings describe the “perfect anti-arthritic agent”; acceptance by KOLs offers unprecedented prospects.
Read the full report

Client:
UCB (under licence with Almirall Prodesfarma)
Category:
Musculoskeletal